[Sunitinib induces autophagy via suppressing Akt/mTOR pathway in renal cell carcinoma]

P Cao1, X J Jiang2, Z J Xi1

  • 1Department of Urology, Peking University First Hospital; Institute of Urology, Peking University, Beijing 100034, China.

Abstract

Insights

Sunitinib triggers autophagy in renal cell carcinoma by inhibiting the Akt/mTOR pathway. This autophagy plays a role in cancer cell apoptosis, offering insights into targeted cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Renal cell carcinoma (RCC) is a significant health concern.
  • Sunitinib is a targeted therapy used in RCC treatment.
  • The precise mechanism of sunitinib's action, particularly its effect on cellular processes like autophagy, requires elucidation.

Purpose of the Study:

  • To investigate the mechanism by which sunitinib induces autophagy in renal cell carcinoma cells.
  • To determine the role of autophagy in sunitinib-induced apoptosis.
  • To identify the specific molecular pathways targeted by sunitinib in this context.

Main Methods:

  • Cell viability was assessed using MTS assays.
  • Autophagy and apoptosis were measured after knocking down Beclin1 and LC3 using RNA interference.
  • Transmission electron microscopy and fluorescence microscopy were used to observe autophagosome formation and LC3-II dynamics.
  • Protein expression levels of LC3-II, Akt/mTOR, and PARP were analyzed via immunoblotting.

Main Results:

  • Sunitinib significantly reduced ACHN cell viability in a dose- and time-dependent manner.
  • Knocking down autophagy-related proteins increased apoptosis, indicated by PARP cleavage.
  • Sunitinib treatment led to increased autophagic vacuoles and LC3-II accumulation, confirming enhanced autophagy.
  • Inhibition of the Akt/mTOR pathway was observed, suggesting it as a key target for sunitinib-induced autophagy.

Conclusions:

  • Sunitinib induces autophagy in renal cell carcinoma cells by suppressing the Akt/mTOR signaling pathway.
  • The induced autophagy is implicated in the apoptotic process of cancer cells.
  • Understanding this mechanism may inform the development of more effective RCC treatments.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.9K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.8K